Physician profile
Kaleb B Smithson
NPI 1659767531
$7,436.99
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $444 · 2021: $6,397 · 2022: $185 · 2023: $383 · 2024: $28.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $4,786.72 | 2021 | |
| Stryker Corporation | $992.10 | 2021-2023 | T2 |
| Skeletal Dynamics INC | $272.58 | 2021 | |
| Aptis Medical, LLC | $243.43 | 2021 | |
| Liberty Surgical INC. | $242.00 | 2020 | |
| Acumed LLC | $202.40 | 2020 | |
| Midsouth Orthopedics INC. | $135.57 | 2021 | |
| Axogen | $123.71 | 2021 | |
| Checkpoint Surgical, INC | $107.45 | 2021 | |
| Polynovo North America LLC | $80.11 | 2023 | |
| Djo, LLC | $76.63 | 2023-2024 | Cmf |
| Trimed, INC. | $66.28 | 2022 | |
| Kerecis Limited | $31.31 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Abbvie INC. | $30.73 | 2023 | Dalvance |
| Bioventus LLC | $30.22 | 2023 | Durolane |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $15.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaleb Smithson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.